Gabapentin
Product Images NDC 42254-049

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 42254-049). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

7d5ebe51-figure-01 (1bc85f95 C26a 4037 A02a 2248f6518fe2 01)

Chemical structure of gabapentin showing a cyclohexane ring with amino (CH2NH2) and acetic acid (CH2CO2H) functional groups attached, consistent with its molecular configuration.*

FDA Label Image

7d5ebe51-figure-02 (1bc85f95 C26a 4037 A02a 2248f6518fe2 02)

A line graph comparing mean pain scores over eight weeks between placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, and the y-axis shows mean pain scores from 0 to 9. Gabapentin shows a marked decrease in pain scores compared to placebo during a 4-week dose titration and a 4-week fixed dose period.*

FDA Label Image

7d5ebe51-figure-03 (1bc85f95 C26a 4037 A02a 2248f6518fe2 03)

A line graph depicting mean pain scores over a 7-week study period comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration period and a 4-week fixed dose period, while the y-axis shows mean pain scores from 0 to 10. Both Gabapentin dose groups show a significant reduction in pain compared to placebo.*

FDA Label Image

7d5ebe51-figure-04 (1bc85f95 C26a 4037 A02a 2248f6518fe2 04)

A bar graph showing the percentage of responders at endpoint in two different studies comparing placebo (PBO) with Gabapentin (GBP) at various dosages. Study 1 compares PBO to GBP 3600 mg with significant differences marked, while Study 2 compares PBO to GBP 1800 mg and GBP 2400 mg, both showing higher responder percentages with statistical significance indicated.*

FDA Label Image

7d5ebe51-figure-05 (1bc85f95 C26a 4037 A02a 2248f6518fe2 05)

A scatter plot illustrating differences in percentage on the y-axis versus daily gabapentin dose in milligrams on the x-axis. The chart compares three studies labeled as Study a, Study b, and Study c with data points for daily doses of 600, 900, 1200, and 1800 mg. Each study's data points are represented with distinct markers and indicate variation in the percentage difference at each dose level.*

FDA Label Image

Gabapentin 300mg (1bc85f95 C26a 4037 A02a 2248f6518fe2 06)

Gabapentin 300mg capsules packaging label by Physician Partner, a division of Rebel Distributors Corp. The label indicates 90 capsules per package, each containing 300mg of Gabapentin, USP. Capsules are described as hard gelatin size 1 with yellow opaque cap and body, imprinted with "300mg" and "IG322." The label includes NDC 42254-049-90 and manufacturer Invagen Pharmaceuticals, Inc., Hauppauge, NY. Storage instructions specify controlled room temperature and keeping medication out of children's reach.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.